CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jason Kelly

Co-Founder and Chief Executive Officer, Ginkgo Bioworks Holdings, Inc.

Search every verified Jason Kelly interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On October 8, 2026, Jason Kelly co-hosted an episode of The Deal with Alex Rodriguez, featuring Olympian Gabby Thomas. During the conversation, Thomas discussed her role in co-founding the Athlos track and field league with entrepreneur Alexis Ohanian, including the league's structure, its focus on providing equity to athletes, and her vision for expanding it beyond single events. Kelly participated in the discussion, engaging with Thomas on topics such as the business model of the league and the broader growth of women's sports.

Recent appearances

Verified interview transcripts

Notable quotes

“When it comes to China, there's been a real shift in the way that our industry works in biotech. The majority of it is drug development. The way the game is played is you'll have maybe about half your drugs made within the R&D departments of the large pharma companies, and then you have a whole biotech sector that is like a bunch of startups. Rewind the clock 5 years, of those acquired startups, roughly 0%, less than”

“We've gone from effectively 0% of acquired new drug assets and less than $2 billion worth back in five years ago coming from China to last year or 130 billion and 48%. Like crazy shift to moving the startup ecosystem to China. And so, that's the big wakeup call. So, there's a lot of activity on this right now. There's a new thing called BINSA which basically is to add biotech to something called the coins act which i”

“Let me tell you what the absolute biggest pile of money in the entire freaking world is that's in the future. It's longevity and wellness for human beings into the later ages of their life. It's like infinity pile of money. Like what is what? Like we are starting to get a taste of this because like of the GLP-1s are like a truly consumer product. Biotech product. I mean Lilly and Novo's what were like a trillion doll”

“I think the way you make a big tools company, this is basically what I'm trying to do now, but like the way you make a big tools company is you use the fact that there is a good tools industry right now. But actually, you know, Thermo Fisher is a 200 billion plus market cap company. Danaher and the two of them are kind of the whatever the Google and Amazon cloud, you know, like they're the ones who provide everything”

“Pharma industry spends close to $80 billion a year on research, not clinical trials, but just on labs and people in the labs and this type of stuff. The NIH spends $40 billion a year on the same stuff. So, we're talking like 120 billion that's being spent largely on manual labs. All right. So, that's like that's my market. That's what I'm going after. I think that could be ma- You could get way more out of that 120 b”

“The experiment we did with OpenAI, we let GPT-5 design 30,000 experiments a week for 6 weeks. We had a benchmark against this lab at Stanford, my Jewett's lab, who had produced a certain amount of in this case protein per dollar. It's like useful for manufacturing drugs and things like that. And we said, 'Could you beat it?' And after the fourth round, it had beat it. And after the sixth round, we beat it by 40%. And”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →